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Testosterone replacement in young male cancer
survivors (TRYMS) - pragmatic adaptation of trial
design for a trial struggling with recruitment
Isabelle Smith1*, Jayne Swain1, Helen Marshall1, Alexandra Smith1, Jennifer Walsh2, Richard Ross2, Sarah Brown1
From 3rd International Clinical Trials Methodology Conference
Glasgow, UK. 16-17 November 2015
TRYMS is a multicentre, randomised, double-blinded,
parallel group, placebo controlled phase IV trial in young
male cancer survivors with low testosterone levels. The
trial is designed to investigate whether testosterone
treatment for 26 weeks will result in a reduction of truncal
fat mass and increase in participant-reported physical
functioning scores.
The general consensus worldwide is that testosterone
levels ≤12nmol/L are deemed to be low; however a pre-
vious study of 200 healthy volunteers found that testos-
terone≤10nmol/L would be deemed to be low. The trial
team considered only including patients with testoster-
one≤10nmol/L but acknowledged this would leave an
evidence gap for patients with testosterone between
10-12nmol/L. Therefore TRYMS was designed to
determine whether testosterone replacement is effective
in men with low testosterone and with borderline low
testosterone by powering the study to look at each sub-
group individually. A sample size of 268 participants
was required after accounting for imbalanced recruit-
ment to the subgroups.
However, opening TRYMS took longer than anticipated
and recruitment was substantially slower than expected;
the trial design was adapted to combine the subgroups
for primary analysis, reducing the minimum sample size
to 112 participants. The trial was granted a recruitment
extension and continued to recruit beyond the minimum
sample size to maximise precision of the treatment effect
estimates in each subgroup; this analysis is exploratory
but still considered useful to inform clinical practice.
This adaption of the trial design was a pragmatic
approach for a trial struggling with recruitment, whilst
still able to provide clinically useful results.
Authors’ details
1Leeds Institute of Clinical Trials Research, Leeds, UK. 2University of Sheffield,
Sheffield, UK.
Published: 16 November 2015
doi:10.1186/1745-6215-16-S2-O79
Cite this article as: Smith et al.: Testosterone replacement in young
male cancer survivors (TRYMS) - pragmatic adaptation of trial design for
a trial struggling with recruitment. Trials 2015 16(Suppl 2):O79.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit1Leeds Institute of Clinical Trials Research, Leeds, UK
Full list of author information is available at the end of the article
Smith et al. Trials 2015, 16(Suppl 2):O79
http://www.trialsjournal.com/content/16/S2/O79
TRIALS
© 2015 Smith et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
